Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma.

被引：0
|
作者：
Chari, A
Kaplan, L
Linker, C
Damon, LE
Navarro, WH
Martin, T
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] New York Hosp, New York, NY 10021 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5182
引用
收藏
页码：379B / 379B
页数：1
相关论文
共 50 条
  • [1] Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma
    Ning, Yang-Min
    He, Kun
    Dagher, Ramz
    Sridhara, Rajeshwari
    Farrell, Ann T.
    Justice, Robert
    Pazdur, Richard
    [J]. ONCOLOGY-NEW YORK, 2007, 21 (12): : 1503 - 1508
  • [2] Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: A phase I/II study.
    Berenson, J
    Yang, H
    Swift, R
    Sadler, K
    Vescio, R
    Adams, J
    Schenkein, D
    [J]. BLOOD, 2004, 104 (11) : 64A - 64A
  • [3] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Shigeru Kusumoto
    Kazutaka Sunami
    Mitsuo Inagaki
    Shinsuke Iida
    [J]. International Journal of Hematology, 2015, 101 : 578 - 584
  • [4] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Kusumoto, Shigeru
    Sunami, Kazutaka
    Inagaki, Mitsuo
    Iida, Shinsuke
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 578 - 584
  • [5] Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study
    Voorhees, Peter M.
    Gasparetto, Cristina
    Richards, Kristy L.
    Garcia, Reynaldo
    Strader, John S.
    Ferraro, Madlyn
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic T.
    Dodd, Andrew
    Foster, Matthew C.
    Gabriel, Don A.
    Shea, Thomas C.
    Serody, Jonathan
    van Deventer, Hendrik W.
    Rizvi, Syed
    Orlowski, Robert Z.
    Hurd, David D.
    [J]. BLOOD, 2009, 114 (22) : 129 - 130
  • [6] Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma
    Voorhees, Peter M.
    Gasparetto, Cristina
    Osman, Keren
    Richards, Kristy
    Ferraro, Madlyn
    Garcia, Reynaldo
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic
    Strader, John
    Orlowski, Robert Z.
    Hurd, David Duane
    [J]. BLOOD, 2010, 116 (21) : 815 - 816
  • [7] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] A phase I/II study of bortezomib and low dose intravenous melphalan (BM) for relapsed multiple myeloma.
    Popat, R
    Oakervee, HE
    Foot, N
    Agrawal, S
    Smith, P
    Craddock, C
    Williams, C
    Basu, S
    Cavenagh, JD
    [J]. BLOOD, 2005, 106 (11) : 718A - 718A
  • [10] Pegylated liposomal doxorubicin and bortezomib in relapsed/refractory multiple myeloma
    不详
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 453 - 455
12345